Jonathan is a director at Henslow, Oaklins’ member firm in Australia. He has over 25 years’ professional experience in corporate finance and public markets, with core expertise in ECM and M&A, primarily servicing small to mid-market companies. Jonathan has particularly strong sector expertise in FMCG, financial services and technology. Recent transactions include advising Sensera (ASX:SE1) on its pre-IPO raising and IPO, Hemideina on its seed and series A private capital raisings and Watermark on its divestment to Xenith IP Group (ASX:XIP).
Prior to Henslow, Jonathan was a director and the head of corporate finance at Austock Group, a role he held for over 10 years. Previously, he worked in the corporate departments of two other tier two brokerage firms in Melbourne and Perth, and with the international firm’s corporate planning and development arm. Currently, he is a non-executive director of ASX-listed companies, namely Generation Development Limited (ASX:GDG), Vita Life Sciences (ASX:VSC) and Sensera Limited (ASX:SE1). He is also a member (chair of the investment committee) of the Melbourne Angels, an early-stage investor group focused on high-growth Australian businesses.